Abstract: Compositions and methods of using compositions that induce UBE1L or a ubiquitin-like protein ISG15, or inhibit a deconjugase UBP43 to degrade oncogenic proteins and enhance apoptosis of cancer (neoplastic) or pre-cancerous (pre-neoplastic) cells are provided. Methods for the prevention or treatment of cancer via administration of these compositions are also provided.

Abstract: The present invention is a transgenic non-human animal whose genome contains a transgene containing a nucleic acid encoding a cyclin E protein operably linked to a regulatory element including a lung-specific promoter. The transgenic animals of the present invention have elevated levels cyclin E protein in the lung and have in increased occurrence of lung carcinogenesis. The animals of the instant invention were also found to have increased levels of Gli1 and Shh. Vectors, cells and cell lines are provided, as is a method for identifying a therapeutic agent for the chemoprevention or treatment of lung cancer.

Abstract: Compositions and methods for increasing the efficacy of an epidermal growth factor receptor-tyrosine kinase inhibitor are provided. The drugs are modified stereospecific epidermal growth factor receptor-tyrosine kinase inhibitors that upon modification are able to accumulate at higher levels in tumor cells thereby increasing the efficacy of the inhibitor.

Abstract: The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.

Abstract: The present invention relates to compositions and methods for destabilizing lysosomes to increase the degradation of oncogenic or aberrant proteins for the prevention and treatment of disease. Methods for identifying agents which destabilize lysosomes are also provided as are agents identified in accordance with the screening method.

Abstract: Compositions and methods of using compositions that induce UBE1L or a ubiquitin-like protein ISG15 or inhibit a deconjugase UBP43 to degrade oncogenic proteins and enhance apoptosis of cancer (neoplastic) or pre-cancerous (pre-neoplastic) cells are provided. Methods for the prevention or treatment of cancer via administration of these compositions are also provided.

Abstract: This invention relates to method and apparatus for collection of the complete fluorescence emission spectrum and the transient decay of a selected spectral band simultaneously with data acquisition times of less that one second. This invention is useful for studying human tissues and cells in vivo.

Abstract: The present invention provides genes that are differentially expressed during neoplasia. These genes and gene products comprise panels for use in screening candidate agents for therapeutic intervention in lung cancers, and for use in therapeutic, prognostic and diagnostic methods and compositions. Therapeutic agents are also provided by the invention. Diagnostic compositions include compositions comprising detection agents for detecting one or more genes that have been shown to be up-or down-regulated in pathogenesis of lung cancer. Exemplary detection agents include nucleic acid probes, which can be in solution or attached to a solid surface, e.g., in the form of a microarray. The invention also provides computer-readable media comprising values of levels of expression of one or more genes that are modulated in lung cancer.

Abstract: The present invention provides a method of diagnosing APL in a subject which comprises detecting in a sample from the subject either nucleic acid encoding an abnormal RAR-.alpha. receptor or an expressed protein encoded thereby. The present invention also provides methods of identifying a subject with APL who will or will not respond to treatment with a retinoid, as well as a subjects with APL who do not express a detectable t(15;17) translocation but will or will not respond to treatment with a retinoid. In addition, the present invention provides methods for monitoring the activity of APL and the process of treatment of APL. The present invention provides methods of identifying a subject with a neoplastic condition other than APL who will or will not respond to treatment with a retinoid as well as methods for monitoring the level of disease activity and progress and adequacy of treatment of a neoplastic condition.